Pirenzepine-d8 (dihydrochloride)

Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037) . Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells[1][2][3].

Product Specifications

CAS Number

[2982740-97-4]

Product Name Alternative

LS 519-d8 (dihydrochloride) ; Pirenzepin-d8 (dihydrochloride) ; Gastrozepin-d8 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Isotope-Labeled Compounds; mAChR

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

O=C1NC2=CC=CN=C2N(C(CN3C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C3([2H])[2H])=O)C4=CC=CC=C14.Cl.Cl

Molecular Formula

C19H15D8Cl2N5O2

Molecular Weight

432.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Carmine AA, et al. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985 Aug;30 (2) :85-126.|[2]Yin QQ, et al. Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling. Asian J Androl. 2018 Nov-Dec;20 (6) :608-614.|[3]Yabuki Y, et al. The T-type calcium channel enhancer SAK3 inhibits neuronal death following transient brain ischemia via nicotinic acetylcholine receptor stimulation. Neurochem Int. 2017 Sep;108:272-281.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-246.